Rétinoblastome
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | DIS-RETINOBLASTOMA |
|---|---|
| Type | Maladie |
| Alias | Rétinoblastome héréditaireRétinoblastome pédiatriqueRBRétinoblastome sporadiqueRétinoblastome trilatéralРетинобластома |
| État | reviewed 2026-05-18 | pending_clinical_signoff |
| Maladies | Aucune déclaration |
| Sources | SRC-COG SRC-NCCN-PEDIATRIC-SARCOMA |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 9510/3 |
|---|---|
| icd_o_3_topography | ["C69.2"] |
| icd_10 | C69.2 |
| who_classification | WHO Eye Tumours 5th ed (2024): Retinoblastoma |
Notes
Most common pediatric ocular malignancy. Germline RB1 testing mandatory at diagnosis — drives sibling cascade screening, lifetime second-primary surveillance (osteosarcoma, soft-tissue sarcomas, melanoma; ~50% lifetime risk of second cancer in germline carriers), and treatment choice (avoid external-beam RT in germline carriers because of post-RT sarcoma risk in field). Treatment: intra-arterial melphalan chemo (Group A-B-C eyes) is modern standard with high eye-salvage rates; enucleation for Group D-E or RT-induced cataract / glaucoma; systemic chemo (carboplatin + etoposide + vincristine) for bilateral / disseminated disease.
Utilisé par
Pertinence thérapeutique
BMA-RB1-GERMLINE-RETINOBLASTOMA- Les variantes pathogènes de la germe RB1 provoquent un rétinoblastome héréditaire (~40% de rétinoblastome c...
Maladie
DIS-PINEOBLASTOMA- Pineoblastome